article Open AccessTop 1% cited

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Annals of Neurology · 2009 · Vol. 65(4) · pp. 403–413

Leslie M. Shaw✉(University of Pennsylvania)Hugo Vanderstichele(Fujirebio (Belgium))Małgorzata Knapik-Czajka(University of Pennsylvania)Christopher M. Clark(Institute on Aging)Paul Aisen(University of California, San Diego)Ronald C. Petersen(Mayo Clinic)Kaj Blennow(University of Gothenburg)Holly Soares(Pfizer (United States))Adam J. Simon(United States Military Academy)Piotr Lewczuk(Friedrich-Alexander-Universität Erlangen-Nürnberg)Robert A. Dean(Eli Lilly (United States))Eric Siemers(Eli Lilly (United States))William Z. Potter(United States Military Academy)Virginia M.‐Y. Lee(University of Pennsylvania)John Q. Trojanowski(University of Pennsylvania)Alzheimer's Disease Neuroimaging Initiative

View via DOI Full-text PDF

Abstract

The CSF biomarker signature of AD defined by A beta(1-42) and t-tau in the autopsy-confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD.

Alzheimer's disease research and treatments Dementia and Cognitive Impairment Research Schizophrenia research and treatmentBiomarkerCerebrospinal fluidCohortInternal medicineMedicineReceiver operating characteristicAlzheimer's diseaseLogistic regressionNeuroimagingOncology

MeSH terms

Amyloid beta-PeptidesAgedAged, 80 and overAlzheimer DiseaseCognition DisordersDiagnostic ImagingFemaleHumansMaleMiddle AgedPeptide FragmentsPhosphorylationRetrospective StudiesROC CurveSensitivity and Specificity